FAZPILODEMAB
UNII VVE4UQ5M6P

Substance Identification & Data

This profile provides standardized clinical and technical data for Fazpilodemab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) VVE4UQ5M6P.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2517935-02-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

VVE4UQ5M6P

CAS Registry Number

2517935-02-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

FAZPILODEMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C188644

National Cancer Institute reference terminology for clinical and research data.

INN ID

12017

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

KL-213

Identifier assigned by the United States Adopted Names Council.

Substance Type

Fazpilodemab

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Fazpilodemab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Fazpilodemab

Common Names & Synonyms

ANTI-FGFR1/KLB MAB

BFKB-8488A (BISPECIFIC ANTIBODY DESIGNED TO MIMIC THE METABOLIC HORMONE FGF21).

FAZPILODEMAB [USAN]

Immunoglobulin G1 [369-serine,371-alanine,410-valine], anti-(human β-Klotho protein) (human monoclonal HKLB4206 γ1-chain), disulfide with monoclonal HKLB4206 κ-chain, (229→225'),(232→228')-bis(disulfide) with immunoglobulin G1 [365-tryptophan] anti-(human fibroblast growth factor receptor 1) (human-Mus musculus monoclonal KFGF5226 γ1-chain) disulfide with human-Mus musculus monoclonal KFGF5226 κ-chain

fazpilodemab [INN]

immunoglobulin G1-kappa, anti-[Homo sapiens KLB (klotho beta, b-Klotho)] and anti-[Homo sapiens FGFR1 (fibroblast growth factor receptor 1, FLT2, KAL2)], monoclonal antibody, bispecific; gamma1 heavy chain anti-KLB (1-450) [VH (Homo sapiens IGHV3-66*01 (77.3%) -(IGHD) -IGHJ4*01 (100%), CDRIMGT [8.8.14] (26-33.51-58.96-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, G1v30 CH2 N84.4>G, G1v33 CH3 S22, A24, V86 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 N84.4>G (300) (234-343), CH3 E12 (359), M14 (361), T22>S (369), L24>A (371), Y86>V (410) (344-448), CHS (449-450)) (121-450)], (223-218')-disulfide with kappa light chain anti- KLB (1'-218') [V-KAPPA Musmus/Homsap (Mus musculus IGKV3-5*01 (81.8%) -IGKJ1*01 (83.3%) G120>Q (104), L124>V (108)/Homo sapiens IGKV4-1*01 (79.2%) - IGKJ1*01 (100%), CDR-IMGT [10.3.9] (27-36.54-56.93- 101)) (1'-111') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112'-218')]; gamma1 heavy chain anti-FGFR1 (1''-446'') [VH (Homo sapiens IGHV3-66*01 (86.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.9] (26-33.51-58.97-105)) (1''-116'') -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1, G1v30 CH2 N84.4>G, G1v32 CH3 W22 (CH1 R120>K (213) (117''- 214''), hinge 1-15 (215''-229''), CH2 N84.4>G (296) (230''- 339''), CH3 E12 (355), M14 (357), T22>W (365) (340''- 444''), CHS (445''-446'')) (117''-446'')], (219''-214''')- disulfide with kappa light chain anti-FGFR1 (1'''-214''') [VKAPPA (Homo sapiens IGKV1-39*01 (89.5%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'''-107''') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'''-214''')]; dimer (229-225'':232-228'')- bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1, non-glycosylated